Singular Health Wins FDA Clearance for Cloud-Based 3DICOM MD®, Expanding U.S. Push

Singular Health (ASX: SHG) has notched another milestone in its U.S. regulatory journey, securing FDA 510(k) clearance for its cloud-based 3DICOM MD® software. The nod from the U.S. Food and Drug Administration clears the way for the company’s software-as-a-medical-device (SaMD) to be deployed across healthcare organisations without the traditional burdens of hardware installations.

This latest clearance, announced on 13 January, builds on the company’s October 2022 approval for the desktop version of 3DICOM MD®, and marks a strategic evolution in both form and functionality. With the cloud-based version now approved as a Class II medical device, Singular Health is aiming to tackle one of the U.S. healthcare system’s lingering inefficiencies: unnecessary duplicate imaging.

Rapid Review, Real Impact

The 3DICOM MD® Cloud clearance was achieved in just 40 calendar days — less than half the usual 90-day turnaround for FDA reviews. This accelerated approval reflects the robustness of Singular’s submission and the regulatory confidence carried over from the previously cleared desktop version.

Singular Health CEO Denning Chong highlighted the milestone’s commercial implications:

“This clearance... removes many of the traditional barriers to adoption by eliminating the need for hardware and complex desktop installations, while expanding modality coverage to include X-ray and ultrasound. This positions the Company to scale faster and drive greater impact in reducing duplicate imaging”.

Beyond the Desktop: Now Supporting Five Modalities

One of the major enhancements in the cloud-based 3DICOM MD® is its expanded support for imaging modalities. While the original desktop version handled CT, MRI, and PET, the cloud iteration now includes X-ray and ultrasound — two of the most commonly used modalities in clinical practice. This expansion materially widens the platform’s utility across more clinical scenarios.

By delivering browser-enabled 3D medical imaging capabilities, the company hopes to lower IT barriers for hospital networks, outpatient clinics, and remote practitioners alike. The system facilitates image sharing across sites and multidisciplinary teams, helping to reduce repeat scans due to lack of access to prior imaging.

Eyeing a $16.5 Billion Market

Singular is chasing a big prize. The company estimates the total addressable market (TAM) for reducing duplicate imaging in the U.S. at US$16.5 billion. That figure stems from an estimated 7.7% repeat imaging rate across modalities, based on peer-reviewed data, and an annual imaging spend of roughly US$236.5 billion.

With X-ray and ultrasound now added to the platform, the company has significantly increased the breadth of clinical use cases it can serve. That makes the commercial proposition for larger healthcare organisations more compelling — especially in systems seeking cost-saving digital solutions to streamline care.

What’s Next?

With both desktop and cloud versions of 3DICOM MD® now FDA-cleared, Singular Health is positioned to step up commercial efforts in the U.S., supported by a regulatory backbone and product flexibility that caters to a broad swathe of the market.

For a small-cap medtech out of Western Australia, this is a big leap onto a much larger playing field — one where imaging access, cost-efficiency, and clinical interoperability are key battlegrounds.

With clearance in hand and a cloud-ready platform, Singular now has both the tools and the traction to push further into a highly fragmented U.S. imaging ecosystem. Whether that translates to contracts and revenue will be the real test, but the regulatory groundwork is firmly in place.